Weekly Research Analysts’ Ratings Changes for Cytokinetics (CYTK)

Several brokerages have updated their recommendations and price targets on shares of Cytokinetics (NASDAQ: CYTK) in the last few weeks:

• 7/7/2026 – Cytokinetics had its price target lowered by Royal Bank Of Canada from $119.00 to $117.00. They now have an “outperform” rating on the stock.
• 6/29/2026 – Cytokinetics was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $115.00 price target on the stock, up from $69.00.
• 6/24/2026 – Cytokinetics had its price target raised by Mizuho from $100.00 to $118.00. They now have an “outperform” rating on the stock.
• 6/17/2026 – Cytokinetics had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $119.00 price target on the stock.
• 6/17/2026 – Cytokinetics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $102.00 price target on the stock.
• 5/18/2026 – Cytokinetics is now covered by Citigroup Inc.. They set a “buy” rating and a $99.00 price target on the stock.
• 5/18/2026 – Cytokinetics was upgraded by Citigroup Inc. from “outperform” to “strong-buy”.
• 5/12/2026 – Cytokinetics had its price target raised by JPMorgan Chase & Co. from $92.00 to $97.00. They now have an “overweight” rating on the stock.
• 5/11/2026 – Cytokinetics had its price target raised by HC Wainwright from $136.00 to $140.00. They now have a “buy” rating on the stock.
• 5/9/2026 – Cytokinetics was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Activity at Cytokinetics

In other Cytokinetics news, EVP Fady Ibraham Malik sold 3,500 shares of Cytokinetics stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $86.62, for a total value of $303,170.00. Following the transaction, the executive vice president directly owned 153,902 shares in the company, valued at approximately $13,330,991.24. This trade represents a 2.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $85.80, for a total value of $1,287,000.00. Following the completion of the transaction, the executive vice president directly owned 58,555 shares in the company, valued at approximately $5,024,019. The trade was a 20.39% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 142,985 shares of company stock worth $10,413,592 in the last ninety days. Company insiders own 2.60% of the company’s stock.

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.